+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis



Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis



International Journal of Clinical and Experimental Pathology 8(10): 12084-12092



CD133 is one of the most commonly used markers of pancreatic cancer stem cells (CSCs), which are characterized by their ability for self-renewal and tumorigenicity. Although the expression of CD133 has been reported to correlate with poor prognosis of PDAC in most literatures, some controversies still exist. In this study, we aimed to investigate the correlation between CD133 expression and prognosis and clinicopathological features in PDAC. A search in the Medline, EMBASE and Chinese CNKI (China National Knowledge Infrastructure) database (up to 1 March 2015) was performed using the following keywords pancreatic cancer, CD133, AC133, prominin-1 etc. Data from eligible studies were extracted and included into meta-analysis using a random effects model. Outcomes included overall survival and various clinicopathological features. We performed a final analysis of 723 patients from 11 evaluable studies for prognostic value and 687 patients from 12 evaluable studies for clinicopathological features. Our study shows that the pooled hazard ratio (HR) of overexpression CD133 for overall survival in PDAC was 0.58 (95% confidence interval (CI): 0.49-0.67) by univariate analysis and 0.73 (95% CI: 0.52-1.03) by multivariate analysis. With respect to clinicopathological features, CD133 overexpression by immunohistochemistry (IHC) method was closely correlated with clinical TNM stage (TNM stage III+IV, OR=0.32, 95% CI: 0.19-0.54), tumor differentiation (poor differentiation, OR=0.56, 95% CI: 0.37-0.83), and lymph node metastasis (N1, 3.15, 95% CI: 1.56-6.36) in patients with PDAC. Our meta-analysis results suggest that CD133 is an efficient prognostic factor in PDAC. Overexpression of CD133 was significantly associated with clinical TNM stage, tumor differentiation and lymph node metastasis.

(PDF emailed within 1 workday: $29.90)

Accession: 058637656

Download citation: RISBibTeXText

PMID: 26722393


Related references

Expression of CD133 cancer stem cell marker in melanoma: a systematic review and meta-analysis. International Journal of Biological Markers 31(2): E118-E125, 2017

Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. Plos One 8(3): E59154, 2013

Prognostic value of cancer stem cell marker CD133 expression in esophageal carcinoma: A meta-analysis. Molecular and Clinical Oncology 4(1): 77-82, 2016

Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review. International Journal of Clinical and Experimental Pathology 6(11): 2644-2650, 2014

Prognostic Value of Cancer Stem Cell Marker ALDH1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Plos One 10(12): E0145164, 2016

Clinicopathological significance and prognostic value of the expression of the cancer stem cell marker CD133 in hepatocellular carcinoma: a meta-analysis. Tumour Biology 36(10): 7623-7630, 2016

Prognostic role of HER2 amplification based on fluorescence in situ hybridization (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis. World Journal of Surgical Oncology 14(1): 38, 2016

Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis. Plos One 9(6): E100168, 2015

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis. Disease Markers 2017: 3276806, 2018

Prognostic value of cancer stem cell marker CD133 in ovarian cancer: a meta-analysis. International Journal of Clinical and Experimental Medicine 8(3): 3080-3088, 2015

Clinicopathological characteristics and prognostic value of cancer stem cell marker CD133 in breast cancer: a meta-analysis. Oncotargets and Therapy 10: 859-870, 2017

Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas. Bmc Cancer 8: 48, 2008

Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance. International Journal of Clinical and Experimental Pathology 5(8): 754-761, 2013

L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma. Journal of Surgical Oncology 103(7): 669-673, 2011

Immunohistochemical expression of NEDD9, E-cadherin and γ-catenin and their prognostic significance in pancreatic ductal adenocarcinoma (PDAC). Bosnian Journal of Basic Medical Sciences 18(3): 246-251, 2018